AI assistant
Sending…
AFT PHARMACEUTICALS LIMITED — Share Issue/Capital Change 2021
Sep 5, 2021
64327_rns_2021-09-05_4356f611-65d2-4679-bdb6-f5b986604b61.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
==> picture [159 x 86] intentionally omitted <==
Capital Change Notice
6 September 2021
Issue of ordinary shares
This notice is given under NZX Listing Rule 3.13.1 and relates to the issue of ordinary shares in AFT Pharmaceuticals Limited under the AFT Pharmaceuticals Limited Long Term Incentive Plan.
Section 1: Issuer information
| Section 1: Issuer information | Section 1: Issuer information |
|---|---|
| Name of issuer | AFT Pharmaceuticals Limited |
| NZX ticker code | AFT |
| Class of financial product | Ordinary shares |
| ISIN (If unknown, check on NZX website) | NZAFTE0001S4 |
| Currency | NZD |
| Section 2: Capital change details | |
| Number issued | 10,000 |
| Nominal value (if any) | Not applicable |
| Issue price per security | $2.80 |
| Nature of the payment | Not applicable |
| Amount paid up (if not in full) | In full |
| Percentage of total class of Financial Products issued(calculated on the number of Financial Products of theClass, excluding any Treasury Stock, in existence) | 0.01% |
| For an issue of Convertible Financial Products orOptions, the principal terms of Conversion | Not applicable |
| Reason for issue and specific authority for issue | 10,000 shares were issued to anemployee exercising options under theAFT Pharmaceuticals Limited LongTerm Incentive Plan |
| Total number of Financial Products of the Class afterthe issue (excluding Treasury Stock) and the totalnumber of Financial Products of the Class held asTreasury Stock after the issue. | 104,688,875 |
| Specific authority for the issue, including a referenceto the rule pursuant to which the issue is made | Directors’ resolution, Listing Rule 4.6 |
| Terms or details of the issue (for example: restrictions,escrow arrangements) | The ordinary shares issued rank paripassu with the existing ordinary shares |
| Date of issue | 6 September 2021 |
AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969 [email protected]
| Section 3: Authority for this announcement and contact person | Section 3: Authority for this announcement and contact person |
|---|---|
| Name of person authorised to make thisannouncement | Malcolm Tubby |
| Contact person for this announcement | Malcolm Tubby |
| Contact phone number | +64 9 488 0232 |
| Contact email address | [email protected] |
| Date of release through MAP | 6 September 2021 |
AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969 [email protected]
More from AFT PHARMACEUTICALS LIMITED
Notice of Dividend Amount
2026
May 25
Regulatory Filings
2026
May 24
Notice of Dividend Amount
2026
May 21
Share Issue/Capital Change
2026
May 21
Earnings Release
2026
May 20
Earnings Release
2026
May 20
Investor Presentation
2026
May 20
Annual Report
2026
May 20
Notice of Dividend Amount
2026
May 20
Board/Management Information
2026
May 17